We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcutis Biotherapeutics, Inc. is a member of our Medical group, which includes 979 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARQT's full-year earnings has moved 25.7% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ARQT has gained about 6% so far this year. In comparison, Medical companies have returned an average of -7.4%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Tenet Healthcare (THC - Free Report) . The stock has returned 31.2% year-to-date.
For Tenet Healthcare, the consensus EPS estimate for the current year has increased 24.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 489 individual stocks and currently sits at #147 in the Zacks Industry Rank. Stocks in this group have lost about 0.4% so far this year, so ARQT is performing better this group in terms of year-to-date returns.
In contrast, Tenet Healthcare falls under the Medical - Hospital industry. Currently, this industry has 5 stocks and is ranked #62. Since the beginning of the year, the industry has moved +18.9%.
Investors interested in the Medical sector may want to keep a close eye on Arcutis Biotherapeutics, Inc. and Tenet Healthcare as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arcutis Biotherapeutics, Inc. is a member of our Medical group, which includes 979 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Arcutis Biotherapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ARQT's full-year earnings has moved 25.7% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ARQT has gained about 6% so far this year. In comparison, Medical companies have returned an average of -7.4%. This shows that Arcutis Biotherapeutics, Inc. is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Tenet Healthcare (THC - Free Report) . The stock has returned 31.2% year-to-date.
For Tenet Healthcare, the consensus EPS estimate for the current year has increased 24.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 489 individual stocks and currently sits at #147 in the Zacks Industry Rank. Stocks in this group have lost about 0.4% so far this year, so ARQT is performing better this group in terms of year-to-date returns.
In contrast, Tenet Healthcare falls under the Medical - Hospital industry. Currently, this industry has 5 stocks and is ranked #62. Since the beginning of the year, the industry has moved +18.9%.
Investors interested in the Medical sector may want to keep a close eye on Arcutis Biotherapeutics, Inc. and Tenet Healthcare as they attempt to continue their solid performance.